Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671502 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
NCT00671502: Completed Phase 3 study, sponsored by Meda Pharmaceuticals.
NCT00671502 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 840 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00671502, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo.
Primary Outcome
the scale used was from 0 to 100 mm. 0 equaled no pain and 100 equaled maximum pain.participants measure their pain before treatment and during treatment at each visit
Interventions
- DRUG Placebo
- DRUG Carisoprodol SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
What the finished NCT00671502 record still lists
NCT00671502 is an interventional study that assigns participants to a tested intervention. The registered 840 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00671502 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00671502 about?
NCT00671502 is a clinical study titled "A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back". The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo.
What is the current status of trial NCT00671502?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2008-04. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00671502?
The interventions under investigation include: Placebo (DRUG), Carisoprodol SR (DRUG).
Who is sponsoring clinical trial NCT00671502?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00671502's enrollment target sits among peer trials
840 392nd of 2000 higher than 1,607 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia